agn-232411
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2015 (NCT02420730)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- fMet-Leu-Phe receptorAGONIST
FPR1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- agn-232411
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05372107 | Phase 1 | Jun 13, 2022 | Allgenesis Biotherapeutics Inc., ORA, Inc. |
| NCT02420730 | Phase 1 | Jun 1, 2015 | Allergan |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 1 | 1 | 1 | 2015 |
| Allgenesis Biotherapeutics Inc. | For profit | 1 | 1 | 1 | 2022 |
| ORA, Inc. | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1